Kevin Dalby

School of Pharmacy University of Texas at Austin, Austin, Texas, U.S.A. 
"Kevin Dalby"
Mean distance: 7.56
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Perry NA, Fialkowski KP, Kaoud TS, et al. (2019) Arrestin-3 interaction with maternal embryonic leucine-zipper kinase. Cellular Signalling. 109366
Qi R, Walker B, Jing Z, et al. (2019) Computational and Experimental Studies of Inhibitor Design for Aldolase A. The Journal of Physical Chemistry. B
Harger M, Lee JH, Walker B, et al. (2019) Computational insights into the binding of IN17 inhibitors to MELK. Journal of Molecular Modeling. 25: 151
Du L, Anderson A, Nguyen K, et al. (2019) JNK2 is required for tumorigenic properties of melanoma cells. Acs Chemical Biology
Sammons RM, Perry NA, Li Y, et al. (2019) A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. Acs Chemical Biology
Veloria J, Shin M, Devkota AK, et al. (2019) Developing Colorimetric and Luminescence-Based High-Throughput Screening Platforms for Monitoring the GTPase Activity of Ferrous Iron Transport Protein B (FeoB). Slas Discovery : Advancing Life Sciences R & D. 2472555219844572
Del Mundo IMA, Cho EJ, Dalby KN, et al. (2019) A tunable assay for modulators of genome-destabilizing DNA structures. Nucleic Acids Research
Hassan AA, Aly AA, Mohamed NK, et al. (2019) Design, synthesis, and DNA interaction studies of furo-imidazo[3.3.3]propellane derivatives: Potential anticancer agents. Bioorganic Chemistry. 85: 585-599
Perry NA, Kaoud TS, Ortega OO, et al. (2018) Arrestin-3 scaffolding of the JNK3 cascade suggests a mechanism for signal amplification. Proceedings of the National Academy of Sciences of the United States of America
Devkota AK, Veloria JR, Guo HF, et al. (2018) Development of a High-Throughput Lysyl Hydroxylase (LH) Assay and Identification of Small-Molecule Inhibitors against LH2. Slas Discovery : Advancing Life Sciences R & D. 2472555218817057
See more...